Dose Escalation Data from transcendIT-101, Ascendis

- Early signs of clinical activity were observed in patients receiving TransCon TLR7/8 Agonist as monotherapy or in combination with pembrolizumab;...

Related Keywords

Copenhagen ,Køavn ,Denmark ,Germany ,New Jersey ,United States ,Palo Alto ,California ,Redwood City ,Heidelberg ,Baden Wüberg ,Berlin ,Diwakar Davar ,Ascendis Pharma ,Stina Singel ,Head Of Clinical Development ,Society For Immunotherapy Of Cancer ,University Of Pittsburgh Medical Center ,Pittsburgh Medical Center ,Senior Vice President ,Clinical Development ,First In Human Dose Escalation ,Dose Expansion Study ,Combination With Pembrolizumab ,Patients With Locally Advanced ,Metastatic Solid Tumor Malignancies ,Initial Results From Phase ,Nasdaq Asnd ,